Kornimate/medical-research-clean huggingface dataset:
comparision of visual outcomes and patient satisfaction between two diffractive trifocal intraocular lenses

Conditions: Cataract Senile

Summary: the purpose of the present study was to compare the clinical outcomes such as visual function, refraction errors and visual quality of patients undergoing cataract surgery with implantation of two different models of diffractive trifocal iols: rayone trifocal (rayner iol, ltd.) and acrysof iq panoptix (alcon laboratories, inc.) iol.

cataract is affecting over 95 million people worldwide and remains the leading cause of vision impairment and blindness. cataract surgery is an effective method for restoring visual acuity (va). with the advancement of cataract surgery technique and intraocular lenses (iol) technologies, expectations of patients from cataract surgery have good vision at distance and near ranges without using spectacles. the standard iols design were monofocal, which offered only fixed focal distance. one of the main factors for dissatisfaction after monofocal pseudophakic eyes is lack of accommodation. previous studies demonstrated that this problem can be resolved by using diffractive trifocal iols. diffractive trifocal iols provide effective near, intermediate and distance visual restoration, and has been widely used in patients who want to achieve spectacle independence after surgery. however, some possible optical side effects of trifocal iols have been reported, including halos and other dysphotopsias, reduced contrast sensitivity (cs), glare disability, which can significantly affect visual quality and patient satisfaction. the purpose of the present study was to compare the clinical outcomes such as visual function, refraction errors and visual quality of patients undergoing cataract surgery with implantation of two different models of diffractive trifocal iols: rayone trifocal (rayner iol, ltd.) and acrysof iq panoptix (alcon laboratories, inc.) iol.

Eligibility criteria:
inclusion criteria: * patients underwent cataract surgery with trifocal intraocular lenses implantation in one or both eyes exclusion criteria: * amblyopia * axial length (al) over 25 mm * previous history of corneal or refractive surgery * ocular comorbidity (corneal scars, keratoconus, and corneal endothelial dystrophy, chronic or recurrent uveitis, macular degeneration, diabetes mellitus with retinal changes, glaucoma or intraocular pressure equal or higher than 24 mmhg) * patient inability to understand and/or fill in patient questionnaires
accelerated vaccination schedule against hepatitis b virus with combined hepatitis a and b vaccine among hemodialysis patients

Conditions: Hepatitis B; Hemodialysis Complication

Summary: the aim of this study is to examine the result of seroprotection using the accelerated vaccination schedule in vaccination of hemodialysis patient through using combined hepatitis a and b vaccine.


Eligibility criteria:
inclusion criteria: * age was above 18 years * hemodialysis patient * all patients had undetectable hepatitis b virus surface antigen and antibody exclusion criteria: * a positive serum hepatitis b virus surface antigen and antibody * patient received a previous course of hepatitis b virus vaccine
study evaluating tigecycline versus ceftriaxone in complicated intra-abdominal infections & community acquired pneumonia

Conditions: Community Acquired Bacterial Pneumonia; Complicated Intra-Abdominal Infection

Summary: the main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (ciai) and community acquired pneumonia (cap).


Eligibility criteria:
inclusion criteria: * male or female subjects 8 to 17 years old. children with bone maturation less than 8 years old should be enrolled with caution due to potential risk of tooth discoloration. * have a diagnosis of a serious infection (complicated intra-abdominal infections \[ciai\] or community acquired pneumonia \[cap\] as applicable) requiring hospitalization and administration of iv antibiotic therapy. * criteria related indication (ciai or cap - as applicable), e.g., sign of systemic infection, signs and symptom. exclusion criteria: * subject with any concomitant illness/condition that, in the investigator's judgment, will substantially increase the risk associated with the subject's participation in and/or completion of the study, or could preclude the evaluation of the subject's response (e.g., life expectancy \<30 days).

Keywords: children pediatry pneumonia intra-abdominal infection
features of the clinical course and prognosis in patients with idiopathic pulmonary hypertension when using modern strategies of specific therapy

Conditions: Idiopathic Pulmonary Arterial Hypertension

Summary: this study will be performed based on a retrospective analysis of the cases of 150-170 patients with ipah observed at the research institute of clinical cardiology over the past 10 years, for a comparative assessment of the survival of groups of patients with ipah diagnosed in the period 2004-2013 and 2014-2023. the demographic, clinical, functional, hemodynamic characteristics of patients, comorbidity, blood biomarker levels, received pah-specific and symptomatic therapy will be assessed in order to determine the clinical characteristics of patients with ipah. the prospective part of study will include 50 patients with ipah.


Eligibility criteria:
inclusion criteria: * age over 18 years; * verified diagnosis of ipah exclusion criteria: * age under 18 years; * other etiology op pah, * ischemic heart disease confirmed by msct of the coronary arteries or coronary angiography; * diseases of the musculoskeletal system that prevent 6mwt * severe liver dysfunction (more than 9 points on the child-pugh scale, class c) * severe renal dysfunction (cc less than 15 ml/min), need for hemodialysis
assessment of outpatient digital follow-up of patients over 70 years of age undergoing chemotherapy treatment

Conditions: Breast Cancer; Colorectal Cancer; Lung Cancer

Summary: adherence of digital follow-up in a population of elderly patients.

the use of digital self-questionnaires adapted to elderly patients but also to brc and bac could detect the toxicities of chemotherapy and we formulate the hypothesis that the continuous monitoring of these different variables in elderly patients treated with chemotherapy is possible and acceptable to this population.

Eligibility criteria:
inclusion criteria: 1. age ≥ 70 years, 2. patient with an indication of adjuvant chemotherapy showing: * breast cancer * colorectal cancer * lung cancer 4. who ≤ 3 (who index - world health organization) 5. estimated life expectancy\> 6 months 6. patients with a smartphone or tablet with an internet connection. it can also be offered to patients whose primary caregiver or the person of trust (including the partner) has a smartphone, an internet connection or a tablet provided that he or she is present more than three times during the week. during chemotherapy to ensure smooth weekly data transfer and filling of questionnaires 7. signed consent to participation 8. affiliation to, or beneficiary of, a social security scheme exclusion criteria: 1. person in emergency situation, person of legal age subject to a legal protection measure (major under guardianship, guardianship or court order), or unable to express his / her consent 2. impossibility of submitting to the medical examination of the test for geographical, social or psychological reasons 3. contraindications to the procedure of the study: patient or caregiver living with a patient who does not have a smartphone with an internet connection (patient or caregiver living with a patient) 4. concurrent participation in another clinical trial 5. patient unable to understand the quality of life survey and patient reported outcome

Keywords: elderly population digital monitoring
short course of bortezomib in anemic patients with refractory cold agglutinin disease

Conditions: Refractory Cold Agglutinin Disease

Summary: this multicenter, phase ii, open label study will enroll patients with chronic cold agglutinin disorder. a single course of bortezomib will be given at the dose of 1,3 mg/sqm iv on days 1, 4, 8, 11.

based on its activity in mm, single agent bortezomib was tested in phase ii trials in lymphoplasmacytic lymphoma, the disorder most frequently associated with cad, and achieved 40-80% responses. these striking clinical responses indicate that proteasome activity is critical for the survival of immunoglobulin-secreting cells. the resolution of transfusion requirement in two patients with refractory cad associated with igmk monoclonal gammopathy has been reported after treatment with a short course of bortezomib. it may be interesting to test the efficacy of bortezomib in a larger series of patients with refractory cad, idiopathic or associated with an otherwise asymptomatic b cell clonal disorder, and to evaluate the duration of clinical benefit.

Eligibility criteria:
inclusion criteria: * patients with chronic cold agglutinin disorder requiring or with a hemoglobin concentration below 10g/l determined at least monthly during the two months before entering the trial; * failure of at least one previous treatment attempt; * hemoglobin level assessment; * presence of serum cold agglutinin (ca). if an overnight incubation is used for ca detection, a titer at 4°c of 64 or higher is required; * written informed consent. exclusion criteria: * presence of a concomitant lymphoproliferative disorder requiring specific treatment for reasons other than cold agglutinin related hemolytic anemia; * preexisting peripheral neuropathy; * known hypersensitivity to bortezomib; * non-cooperative behaviour or non-compliance; * psychiatric diseases or conditions that might impair the ability to give informed consent; * patients who are pregnant (women of childbearing potential must have a negative serum pregnancy test). post-menopausal women must be amenorrhoic for at least 24 months to be considered of non-childbearing potential. male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drug.

Keywords: refractory cold agglutinin disease bortezomib blood-transfusion
treatment of menstrual migraine with sequential, transdermal, 17-beta-estradiol. a double-blind, randomised, cross-over trial.

Conditions: Migraine

Summary: the purpose of this study is to determine whether transdermally administered 17-beta estradiol sequentially could reduce the number of, and severity of, menstrual migraine attacks.

during the fertile ages, migraine is more common in women than in men (3:1). hormonal factors has been proposed to affect this difference and it has been shown that a rapid decrease in serum concentrations of estrogens might trigger an attack.about 15 percent of all women with migraine suffer from menstrual migraine which means that the attacks only come during the menstrual period and start +/- 24 hours of the bleeding start, i.e when there is a rapid decrease in serum concentrations of sex hormones. stabilizing the serum concentrations of estrogens seems to be crucial in the prophylactic treatment of menstrual migraine. a number of studies have focused on treatment with estradiol during the menstrual cycle but results are conflicting and doses and control groups have varied a lot. other studies have tried to reduce the exposition of estrogens by treatment with, for example, gnrh analogues. this treatment stabilizes the woman's serum concentrations of sex hormones on a very low level, like during the menopause, and it seems to be effective but there are a number of side-effects and the treatment is expensive. comparison: in a double-blind, randomized cross-over trial women with strictly defined menstrual migraine will receive treatment with 100 microg 17-beta estradiol/placebo transdermally one week before the estimated start of the menstrual bleeding and twoo weeks on. after three cycles and a wash-out period the treatment will be repeated but now with the tratment the woman did not have during the first treatment period. the women serve as their own controls.

Eligibility criteria:
inclusion criteria: * migraine only during the menstrual period * migraine attacks each menstrual period during the last year * regular menstrual cycle exclusion criteria: * migraine other times than during the menstrual period * use of hormonal contraceptives (other than depo-provera)during the last three months. * depo-provera injection the last year * history of thrombo-embolism * liver disease * history of malignancy * breast-feeding during the last two months * abortion/miscarriage during the last two months * pregnancy

Keywords: migraine menstrual cycle 17 beta-estradiol transdermal administration
physical activity recommendation behaviour in german mental health nurses

Conditions: Mental Disorder; Physical Activity

Summary: the purpose of this study is to examine the physical activity recommendation behaviour, beliefs, barriers and exercise participation in german nurses working with patients with mental disorders.

physical activity plays an important role in the prevention and treatment of mental disorders. despite the potential mental health benefits, large proportions of patients with mental disorders do not meet the physical activity recommendations. nurses play a key role in the recommendation of physical activity to their patients. there are no previous studies that examine physical activity recommendation behaviour in german nurses. the purpose of this study is to examine the physical activity recommendation behaviour, beliefs, barriers and exercise participation in german nurses working with patients with mental disorders.

Eligibility criteria:
inclusion criteria: * nurse * currently working with patients with mental disorders * at least 18 years old * sufficient german skills for answering the questionnaire exclusion criteria: none

Keywords: physical activity mental disorder recommendation behaviour mental health exercise
telemedicine in cardiac surgery: a pilot study

Conditions: Coronary Artery Disease

Summary: telemedicine has been widely used in managing patients with neurologic disorders or mental illness. telemedicine is defined as the use of medical information exchanged from one site to another via electronic communications for the health and education of the patient or healthcare provider and for the purpose of improving patient care. according to our knowledge, it has not been used to manage cardiac patients who need postoperative care after discharge from hospitals. the use of telemedicine has the potential to reduce the cost of unnecessary travel by assessing the patient's postoperative status prior to making decisions as to whether or not a face-to-face consultation is necessary. in this pilot study we will compare the accuracy of surgeons' decisions during follow-up visits via video-teleconference (v-visit) to surgeons' decisions during traditional face-to-face follow-up visits (ftf-visits). both the v-visit and the ftf-visit will take place at the houston michael e debakey va medical center on the same day. we will also ask both patients and providers to complete short questionnaires after each v-visit regarding their acceptability of using telemedicine for these post-operative follow-up visits. information collected as part of this pilot study will be used to design a future full randomized controlled trial (rct) on the use of telemedicine in evaluating post-operative cardiac surgical patients.

the specific aims are: 1. to compare surgeons' decisions on patient disposition between v-visits and ftf-visits (gold standard). 2. to assess the acceptability to patients and surgeons of using v-visits in the postoperative care of cardiac surgical patients; 3. to assess the technical feasibility of using community-based outpatient clinics (cbocs) for delivery of postoperative cardiac surgical care; 4. to determine the recruitment rate for eligible subjects. we plan to conduct this pilot study at the michael e. debakey veterans affairs medical center (medvamc) in houston, texas, along with satellite cboc facilities in lufkin and conroe. once the accuracy, acceptability, and feasibility of the use of video conferencing (vc) in the postoperative care for cardiac surgical patients are established, we will submit a full proposal to conduct a two-arm rct in future.

Eligibility criteria:
inclusion criteria: 1. patients older than 18 years of age 2. patients who have undergone one of the following cardiac surgical procedures: coronary artery bypass grafting (cabg) and/or cardiac valvular operations exclusion criteria: 1. patients who have undergone aortic dissection/aneurysm operations 2. patients who have been diagnosed with atrial fibrillation

Keywords: telemedicine surgery, cardiac
effect of usage of electroencephalogram (eeg) entropy on the incidence of postoperative cognitive dysfunction in geriatric patients

Conditions: Cognitive Dysfunction

Summary: to determine if the usage of eeg entropy helps to reduces the incidence of pocd in elderly patients after general anesthesia.


Eligibility criteria:
inclusion criteria: * asa physical status i-ii. * scheduled for retinal surgery expected to take 2-3 hours under general anesthesia. * orotracheal intubation. exclusion criteria: * history of cardiac, pulmonary, liver or renal disease. * significant obesity (body mass index \>30. * long-term user of central nervous system activator drugs, benzodiazepines and/or opiates. * dementia, brain atrophy and other neurological disorder.

Keywords: eeg entropy elderly decreases pocd use of eeg entropy geriatric
intensive cholesterol-lowering and cd8+ t cells in prostate cancer

Conditions: Prostate Cancer

Summary: to test the hypothesis that intensive cholesterol lowering (icl) therapy has anti-tumor immune modulating activity, the investigators will conduct an open-label, single-arm phase ii trial in prostate cancer patients who are in active surveillance and undergoing a planned surveillance biopsy in 3-6 months. eligible patients will initiate icl with vytorin®(group 1, 2, and 3), an fda-approved combination of ezetimibe and simvastatin used to lower atherogenic low density lipoprotein cholesterol (ldl-c) or ezetimibe (group 4). starting dose will be determined by current statin use and ldl-c levels. dose modifications of vytorin will be employed with the goal of achieving ldl-c \<70 mg/dl. dose adjustment is not allowed for ezetimibe.


Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form. 2. stated willingness to comply with all study procedures and availability for the duration of the study. 3. at least one atherosclerotic cardiovascular disease (ascvd) risk factor, such as: 1. ≥ 50 years of age 2. hypertension 3. hypercholesterolemia 4. diabetes 5. current or former smoker 6. first-degree family history of any cardiovascular heart disease 7. bmi \> 25 8. on hypertension treatment, statin, and/or aspirin therapy 4. patients with clinically localized prostate cancer. that is low or intermediate risk prostate cancer deﬁned as: 1. pre-operative psa (prostate specific antigen) ≤ 20.0 ng/ml 2. clinical stage t1c or ct2 3. gleason score 3+3 or 3+4 or 4+3 5. patients on as with plans for surveillance biopsy 6. no previous treatment for prostate cancer with radiotherapy, chemotherapy, or hormonal therapy 7. ability to take oral medication and be willing to adhere to once daily, oral vytorin or ezetimibe. 8. agree to avoid consumption of grapefruit and grapefruit juice ≥ one quart per day throughout study duration. exclusion criteria: 1. current use of medications contraindicated for use with a statin such as strong cyp3a4 inhibitors (e.g., itraconazole, ketoconazole, posaconazole, erythromycin, clarithromycin, telithromycin, hiv protease inhibitors, and nefazodone). 2. current use of medications contraindicated for use with ezetimibe (i.e., gemfibrozil, cyclosporine, or danazol). 3. history of allergic or severe reaction to a either study agent. 4. history of moderate or severe myalgia with statin use. 5. acute liver failure or decompensated cirrhosis 6. already on maximum vytorin dose (10/80) 7. already on medication(s) known to interact with vytorin or ezetimibe that may prevent protocol-based escalation of cholesterol-lowering therapy from pre-enrollment baseline. 8. already on a pcsk9 inhibitor
studying the effect of capsinoids on brown fat using infrared thermal imaging.

Conditions: Obesity; Diabetes; Impaired Glucose Tolerance

Summary: the primary hypothesis of this study is that consumption of capsinoids increases brown adipose tissue activity, detectable by infrared thermal imaging. the secondary hypothesis is that consumption of capsinoids can affect an individual's glycaemic response.

it has been recently established that brown adipose tissue (bat) exists in adult humans. bat is a thermogenic tissue which dissipates energy as heat. the primary objective of this study is to use thermal imaging to assess the effect of capsinoids on bat activity in adult humans, and whether there is a relationship between the increase in energy expenditure and bat activity after capsinoids intake. the secondary objective is to investigate whether capsinoids will have an effect on an individual's glycaemic response. lean, healthy male volunteers will be recruited. there will be two test sessions which are randomized, where subjects will consume either capsinoids or placebo capsules, and a standardized amount of white rice (equivalent to 50g carbohydrates). indirect calorimetry will be used to assess energy expenditure before and after consumption of the test meal. thermal imaging of supraclavicular bat, the primary bat depot in humans, will be undertaken using an infrared thermal camera to assess changes in bat temperature. blood glucose levels will be monitored by finger prick blood sampling method. this study aims to investigate whether capsinoids consumption leads to changes in bat temperatures detectable by the infrared thermal camera, to confirm the feasibility of using thermal imaging as a rapid, noninvasive, and reproducible way of studying bat activity thus providing a platform to advance research in this emerging field of human bat.

Eligibility criteria:
inclusion criteria: * chinese ethnicity * male * healthy * age 21 - 30 years * bmi 18.0 - 22.9 kg/m2 * not on any prescribed medication * infrequent spicy food or chilli user (less than 3 times per week) exclusion criteria: * smoker * fasting blood glucose \> 5.5 mmol/l * resting blood pressure \> 140/90 mmhg * any major medical conditions including diabetes, hypertension, cardiovascular disease, thyroid disorders * allergic or intolerant to foods presented in the study